跳转至内容
Merck
CN

52448

Supelco

Ranitidine S-oxide

pharmaceutical impurity standard, ≥95.0% (HPLC)

别名:

Ranitidine Related Compound C (USP), Ranitidine impurity C (PhEur), N-{2-{{{5-[(Dimethylamino)methyl]furan-2-yl}methyl}sulfinyl}ethyl}-N′-methyl-2-nitroethene-1,1-diamine

登录查看公司和协议定价

选择尺寸

关于此项目

经验公式（希尔记法）:
C13H22N4O4S
化学文摘社编号:
73851-70-4
分子量:
330.40
Beilstein:
8395257
MDL编号:
MFCD08063699
UNSPSC代码:
41116107
PubChem化学物质编号:
329757841

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

等级

analytical standard

方案

≥95.0% (HPLC)

保质期

limited shelf life, expiry date on the label

技术

HPLC: suitable
gas chromatography (GC): suitable

杂质

≤10.0% related substances
≤5.0% solvents
≤5.0% water

应用

pharmaceutical (small molecule)

包装形式

neat

储存温度

2-8°C

SMILES字符串

CN\C(NCCS(=O)Cc1ccc(CN(C)C)o1)=C/[N+]([O-])=O

InChI

1S/C13H22N4O4S/c1-14-13(9-17(18)19)15-6-7-22(20)10-12-5-4-11(21-12)8-16(2)3/h4-5,9,14-15H,6-8,10H2,1-3H3/b13-9+

InChI key

SKHXRNHSZTXSLP-UKTHLTGXSA-N

正在寻找类似产品? 访问 产品对比指南

应用

Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

象形图

Health hazardExclamation mark
GHS08,GHS07

警示用语：

Danger

危险声明

H317,H334,H335

预防措施声明

P280 - P302 + P352

危险分类

Resp. Sens. 1 - Skin Sens. 1 - STOT SE 3

靶器官

Respiratory system

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
BCBS7735V

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

J H Kang et al.
Pharmacogenetics, 10(1), 67-78 (2000-03-30)
A non-invasive urine analysis method to determine the in-vivo flavin-containing mono-oxygenase (FMO) activity catalysing N-oxidation of ranitidine (RA) was developed and used to phenotype a Korean population. FMO activity was assessed by the molar concentration ratio of RA and RANO
P Viñas et al.
Journal of chromatography. B, Biomedical sciences and applications, 693(2), 443-449 (1997-06-06)
Ranitidine and its main metabolites, ranitidine N-oxide and ranitidine S-oxide, were determined in plasma and urine after separation using reversed-phase liquid chromatography. The mobile phase consisted of an initial isocratic step with 7:93 (v/v) acetonitrile-7.5 mM phosphate buffer (pH 6)
M H Davies et al.
Journal of hepatology, 22(5), 551-560 (1995-05-01)
We have previously reported an association of impaired S-oxidation with primary biliary cirrhosis. In order to confirm and further define this relationship, we retested S-oxidation capacity via three metabolic pathways and sulphation capacity via a fourth pathway. Metabolism of S-carboxymethyl-L-cysteine
M S Lant et al.
Journal of chromatography, 323(1), 143-152 (1985-04-17)
Reversed-phase high-performance liquid chromatography systems for the separation of ranitidine and its metabolites ranitidine-N-oxide, ranitidine-S-oxide, and desmethylranitidine have been developed for use in high-performance liquid chromatography-mass spectrometry. A direct liquid introduction-high-performance liquid chromatography-mass spectrometry system to analyse qualitatively and quantitatively

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持